Acurx Pharmaceuticals stock analysis
Acurx Pharmaceuticals (3ZO0) Stock Price & Analysis
3ZO0 Stock Chart & Stats
- Day’s Range
- EUR 5.09 - EUR 5.20
- 52-Week Range
- EUR 5.09 - EUR 5.20
- Previous Close
- EUR 5.09
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 5.69M
- Enterprise Value
- -EUR 2.96M
- Total Cash (Recent Filing)
- EUR 9.65M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- -1.54
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- -0.36
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development Progress
Enrollment in the fully funded PATHFINDER trial advances ibezapolstat toward pivotal evidence in recurrent CDI. FDA openness to a pre-NDA discussion creates a defined regulatory path, while successful data could support approval discussions across acute and recurrent infection settings.
Differentiated Antibiotic Profile
The reported bactericidal activity, toxin reduction, and activity against resistant bacteria support a differentiated product profile. Potential microbiome-sparing benefits are strategically relevant in CDI, where recurrence and disruption of beneficial gut organisms are important treatment challenges.
Intellectual Property Protection
Long-dated patent coverage and regulatory exclusivity could protect ibezopolstat from direct competition if approved, extending the period available to recover development costs and build commercial value. Broad international coverage also supports potential partnering or regional commercialization strategies.
Bears Say
Pre-revenue Business Model
Acurx has not yet established recurring product revenue, so its financial performance depends on advancing clinical assets rather than operating cash generation. Continued losses leave future value dependent on successful development, regulatory approval, and eventual commercialization or partnering.
Cash Burn And Financing Dependence
Persistent negative cash flow means Acurx is not self-funding its development programs. Management expects to use equity-line drawdowns, equity offerings, partnerships, or grants, creating ongoing financing dependence and potential dilution before meaningful product revenue begins.
Conditional Clinical Execution Path
The next development phase remains contingent on trial results, government funding, and FDA feedback, while the potential PATHFINDER 2 program could involve about 350 patients and 1.5 to 2 years of enrollment. These conditions create substantial execution and timeline uncertainty.
Acurx Pharmaceuticals News
3ZO0 FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
What is Acurx Pharmaceuticals’s market cap?
When is Acurx Pharmaceuticals’s upcoming earnings report date?
How were Acurx Pharmaceuticals’s earnings last quarter?
Is Acurx Pharmaceuticals overvalued?
Does Acurx Pharmaceuticals pay dividends?
What is Acurx Pharmaceuticals’s EPS estimate?
How many shares outstanding does Acurx Pharmaceuticals have?
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Luci
- Employees
- 4
- Website
- www.acurxpharma.com
- Address
- 259 Liberty Avenue, Staten Island, NY, 10305, US
Acurx Pharmaceuticals (3ZO0) Earnings & Revenues
3ZO0 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, centered on the start of the fully funded PATHFINDER trial, favorable preclinical and microbiome findings, FDA openness to further discussions regarding a potential NDA pathway, expanded intellectual property, and sufficient funding for the current recurrent CDI trial. The main challenges were higher R&D spending, continued net losses, dependence on future funding and clinical data to determine the Phase III pathway, unresolved partnership activity, NASDAQ listing compliance efforts, and the expected timing of a recurrent CDI trial update in the second half of 2027.
View all DE:3ZO0 earnings summaries3ZO0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 8 |
| Technical Analysis | 2 | 1 | 0 |
| Moving Averages | 2 | 2 | 8 |












